Table 2.
Polymerase Chain Reaction (PCR)–Adjusted and Unadjusted Treatment Outcomesa
| Reparasitemia Classification |
PCR-Unadjusted ACPR |
PCR-Adjusted ACPR |
|||||||
| Variable | ETF | LPF | LCF | Reinfection | ACPR, No. | ACPR, % | HR (95% CI) | ACPR, % | HR (95% CI) |
| Day 28 | 2 | 2 | 4 | 1 | 150 | 94.6 | 1.18 | 95.1 | 1.40 |
| Chloroquine | 3 | 0 | 3 | 2 | 162 | 95.5 | (0.46–3.07) | 96.6 | (0.49–4.03) |
| Artemether-Lumefantrine | |||||||||
| Day 42 | 2 | 2 | 6 | 4 | 138 | 91.3 | 1.65 | 93.8 | 1.76 |
| Chloroquine | 3 | 0 | 3 | 3 | 155 | 94.9 | (0.72–3.82) | 96.6 | (0.64–4.83) |
| Artemether-Lumefantrine | |||||||||
| Day 70 | 2 | 3 | 6 | 10 | 114 | 86.4 | 1.36 | 93.1 | 1.67 |
| Chloroquine | 3 | 1 | 3 | 10 | 137 | 89.8 | (0.72–2.57) | 96.0 | (0.65–4.32) |
| Artemether-Lumefantrine | |||||||||
NOTE. ACPR, adequate clinical and parasitological response; CI, confidence interval; ETF, early treatment failure; HR, hazard ratio; LCF, late clinical failure; LPF, late parasitological failure.
a
ACPR percentages were calculated using a survival analysis and, therefore, differ from the percentages calculated by dividing ACPR by ACPR and treatment failures.